New developments in insulin therapy for type 2 diabetes

American Journal of Medicine

Volumn 127, Issue 10, 2014, Pages S39-S48

  Sorli, Christopher ^a  

^a BILLINGS CLINIC   (United States)

Author keywords

Basal insulin; Insulin; Type 2 diabetes

Indexed keywords

BIOD 530; GLUCOSE; HEMOGLOBIN A1C; INCRETIN; INSULIN; INSULIN ASPART; INSULIN ASPART PLUS INSULIN DEGLUDEC; INSULIN DEGLUDEC; INSULIN DEGLUDEC PLUS LIRAGLUTIDE; INSULIN DETEMIR; INSULIN GLARGINE; INSULIN GLULISINE; INSULIN PEGLISPRO; LIXISENATIDE; ORMD 0801; RECOMBINANT HUMAN INSULIN; UNCLASSIFIED DRUG; ANTIDIABETIC AGENT;

ADIPOSE TISSUE; ANTIDIABETIC ACTIVITY; ARTICLE; DIABETIC OBESITY; DRUG ABSORPTION; DRUG DISTRIBUTION; DRUG EFFICACY; DRUG FORMULATION; DRUG MECHANISM; DRUG MEGADOSE; DRUG RESPONSE; DRUG STRUCTURE; DRUG TRANSPORT; GLUCOSE BLOOD LEVEL; GLYCEMIC CONTROL; HEMOGLOBIN BLOOD LEVEL; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN PUMP; INSULIN RESISTANCE; INSULIN TREATMENT; LIVER SINUSOID; NON INSULIN DEPENDENT DIABETES MELLITUS; PHASE 1 CLINICAL TRIAL (TOPIC); PHASE 2 CLINICAL TRIAL (TOPIC); PHASE 3 CLINICAL TRIAL (TOPIC); PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); TISSUE DISTRIBUTION; ANALOGS AND DERIVATIVES; CHEMICALLY INDUCED; CLINICAL TRIAL (TOPIC); DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEM; DRUG EFFECTS; DRUG MONITORING; DRUG SELF ADMINISTRATION; EXPERIMENTAL THERAPY; HYPOGLYCEMIA; INJECTION; MEDICATION COMPLIANCE; PROCEDURES; PSYCHOLOGY; TRENDS; WEIGHT GAIN;

CLINICAL TRIALS AS TOPIC; DIABETES MELLITUS, TYPE 2; DISEASE MANAGEMENT; DRUG DELIVERY SYSTEMS; DRUG MONITORING; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; INJECTIONS; INSULIN; MEDICATION ADHERENCE; SELF ADMINISTRATION; THERAPIES, INVESTIGATIONAL; WEIGHT GAIN;

EID: 84921770360     PISSN: 00029343     EISSN: 15557162     Source Type: Journal    
DOI: 10.1016/j.amjmed.2014.07.006     Document Type: Article

References (97)

1. Brown JB, Nichols GA, Perry A. The burden of treatment failure in type 2 diabetes. Diabetes Care. 2004;27:1535-1540.
2. Peyrot M, Rubin RR, Lauritzen T, et al. Resistance to insulin therapy among patients and providers: results of the cross-national Diabetes Attitudes, Wishes, and Needs (DAWN) study. Diabetes Care. 2005;28: 2673-2679.
3. Kostev K, Mergenthaler U. Time to insulin initiation, glucose control and occurrence of diabetes related complications in France, Germany and UK from 2005 to 2010. Diabetologia. 2011;54(Suppl 1):S159.
4. Moghissi E, King AB. Individualizing insulin therapy in the management of type 2 diabetes. Am J Med. 2014;127(Suppl 1):S3-S10.
5. Ferrannini E. The stunned beta cell: a brief history. Cell Metab. 2010;11:349-352.
6. Bolli GB, Owens DR. Insulin glargine. Lancet. 2000;356:443-445.
7. Peterson GE. Intermediate and long-acting insulins: a review of NPH insulin, insulin glargine and insulin detemir. Curr Med Res Opin. 2006;22:2613-2619.
8. Rosskamp RH, Park G. Long-acting insulin analogs. Diabetes Care. 1999;22(Suppl 2):B109-B113.
9. Heise T, Pieber TR. Towards peakless, reproducible and long-acting insulins. An assessment of the basal analogues based on isoglycaemic clamp studies. Diabetes Obes Metab. 2007;9:648-659.
10. Tibaldi JM. Evolution of insulin: from human to analog. Am J Med. 2014;127(Suppl 1):S25-S38.
11. Jonassen I, Havelund S, Hoeg-Jensen T, et al. Design of the novel protraction mechanism of insulin degludec, an ultra-long-acting basal insulin. Pharm Res. 2012;29:2104-2114.
12. Steensgaard DB, Schluckebier G, Strauss HM, et al. Ligand-controlled assembly of hexamers, dihexamers, and linear multihexamer structures by the engineered acylated insulin degludec. Biochemistry. 2013;52: 295-309.
13. Garber AJ, King AB, Del Prato S, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 2 diabetes (BEGIN Basal-Bolus Type 2): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1498-1507.
14. Heller S, Buse J, Fisher M, et al. Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial. Lancet. 2012;379:1489-1497.
15. Ratner R, Gough SC, Mathieu C, et al. Hypoglycaemia risk with insulin degludec compared with insulin glargine in type 2 and type 1 diabetes: a pre-planned meta-analysis of phase 3 trials. Diabetes Obes Metab. 2013;15:175-184.
16. Zinman B, Philis-Tsimikas A, Cariou B, et al. Insulin degludec versus insulin glargine in insulin-naive patients with type 2 diabetes: a 1-year, randomized, treat-to-target trial (BEGIN Once Long). Diabetes Care. 2012;35:2464-2471.
17. Mathieu C, Hollander P, Miranda-Palma B, et al. Efficacy and safety of insulin degludec in a flexible dosing regimen vs insulin glargine in patients with type 1 diabetes (BEGIN: Flex T1): A 26-week randomized, treat-to-target trial with a 26-week extension. J Clin Endocrinol Metab. 2013;98:1154-1162.
18. Meneghini L, Atkin SL, Gough SCL, et al. The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-totarget trial in people with type 2 diabetes. Diabetes Care. 2013;36: 858-864.
19. Novo Nordisk A/S. NCT01959529. A trial comparing cardiovascular safety of insulin degludec versus insulin glargine in subjects with type 2 diabetes at high risk of cardiovascular events (DEVOTE). Available at: http://clinicaltrials.gov/ct2/show/NCT01959529. Accessed December 12, 2014.
20. Hansen RJ, Cutler GB, Vick A, et al. LY2605541: leveraging hydrodynamic size to develop a novel basal insulin. Diabetes. 2012;61: A228.
21. Sinha VP, Choi SL, Soon DK, et al. Single-dose pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 in healthy subjects. J Clin Pharmacol. 2014;54:792-799.
22. Meier JJ, Veldhuis JD, Butler PC. Pulsatile insulin secretion dictates systemic insulin delivery by regulating hepatic insulin extraction in humans. Diabetes. 2005;54:1649-1656.
23. Russell-Jones D, Khan R. Insulin-associated weight gain in diabetesecauses, effects and coping strategies. Diabetes Obes Metab. 2007;9:799-812.
24. Bergenstal RM, Rosenstock J, Arakaki RF, et al. A randomized, controlled study of once-daily LY2605541, a novel long-acting basal insulin, versus insulin glargine in basal insulin-treated patients with type 2 diabetes. Diabetes Care. 2012;35:2140-2147.
25. Moore M, Smith MS, Sinha VP, et al. Novel pegylated basal insulin LY2605541 has a preferential hepatic effect on glucose metabolism. Diabetes. 2014;63:494-504.
26. Sinha VP, Howey DC, Choi SL, Mace KF, Heise T. Steady-state pharmacokinetics and glucodynamics of the novel, long-acting basal insulin LY2605541 dosed once-daily in patients with type 2 diabetes mellitus. Diabetes Obes Metab. 2014;16:344-350.
27. Rosenstock J, Bergenstal RM, Blevins TC, et al. Better glycemic control and weight loss with the novel long-acting basal insulin LY2605541 compared with insulin glargine in type 1 diabetes: a randomized, crossover study. Diabetes Care. 2013;36:522-528.
28. Eli Lilly and Company. NCT01468987. A study in participants with type 2 diabetes mellitus (IMAGINE 4). Available at: http:// clinicaltrials.gov/show/NCT01468987. Accessed November 15, 2013.
29. Jorgensen KH, Hansen AK, Buschard K. Five fold increase of insulin concentration delays the absorption of subcutaneously injected human insulin suspensions in pigs. Diabetes Res Clin Pract. 2000;50:161-167.
30. Tillner J, Bergmann K, Tiechert L, et al. Euglycemic clamp profile of new insulin glargine U300 formulation in patients with type 1 diabetes (T1DM) is different from glargine U100. Diabetes. 2013;62(Suppl 1): A234.
31. European Patent Office. Insulin glargine U300 European patent application. European patent 2 387 989 A2. November 23, 2011.
32. Steinstraesser A, Schmidt R, Bergmann K, Dahmen R, Becker RH. Investigational new insulin glargine 300 U/ml has the same metabolism as insulin glargine 100 U/ml. Diabetes Obes Metab. 2014. http://dx. doi.org/10.1111/dom.12283. [Epub ahead of print].
33. Sano fi . NCT01499082. Comparison of a new formulation of insulin glargine with lantus in patients with type 2 diabetes mellitus on basal plus mealtime insulin (EDITION I). Available at: http:// clinicaltrials.gov/show/NCT01499082. Accessed December 12, 2014.
34. Sanofi. NCT01499095. Comparison of a new formulation of insulin glargine with lantus in patients with type 2 diabetes on basal insulin with oral antidiabetic therapy (EDITION II). Available at: http:// clinicaltrials.gov/ct2/show/NCT01499095. Accessed November 15, 2013.
35. Riddle MC, Bolli GB, Ziemen M, Muehlen-Bartmer I, Bizet F, Home PD; on behalf of the EDITION 1 Study Investigators. New insulin glargine 300 Units/mL versus glargine 100 Units/mL in people with type 2 diabetes using basal and mealtime insulin: glucose control and hypoglycemia in a 6-month randomized controlled trial (EDITION 1). Diabetes Care . 2014 Jul 30. pii: DC-140991. [Epub ahead of print].
36. Yki-Jarvinen H. An investigational new insulin U300: glucose control and hypoglycemia in people with type 2 diabetes on basal insulin and OADs (EDITION II) (Abstract O-0075). Abstract accepted for presentation at the IDF 2013 World Diabetes Congress, Melbourne, Australia, December 2-6, 2013.
37. Sanofi. NCT01676220. Comparison of a new formulation of insulin glargine with lantus in patients with type 2 diabetes on non-insulin antidiabetic therapy. Available at: http://clinicaltrials.gov/ct2/show/ NCT01676220. Accessed November 15, 2013.
38. Sanofi. NCT01689129. Comparison of a new formulation of insulin glargine with lantus in Japanese patients with Type 1 diabetes mellitus. Available at: http://clinicaltrials.gov/ct2/show/NCT01689129. Accessed November 15, 2013.
39. Sano fi . NCT01683266. Comparison of a new formulation of insulin glargine with lantus in patients with type 1 diabetes mellitus. Available at: http://clinicaltrials.gov/ct2/show/NCT01683266. Accessed November 15, 2013.
40. Pohl R, Hauser R, Li M, et al. BIOD-530 U-400 concentrated recombinant human insulin: pharmacokinetic (PK) and pharmacodynamic (PD) profiles in diabetic swine compared to U-500 regular human insulin (U-500R) and insulin lispro U-100 (IL). Diabetes. 2013;62(Suppl 1):A233.
41. Korsatko S, Deller S, Koehler G, et al. A comparison of the steadystate pharmacokinetic and pharmacodynamic profi les of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Clin Drug Investig. 2013;33:515-521.
42. Heise T, Hermanski L, Nosek L, et al. Insulin degludec: four times lower pharmacodynamic variability than insulin glargine under steadystate conditions in type 1 diabetes. Diabetes Obes Metab. 2012;14: 859-864.
43. Heise T, Nosek L, Bottcher SG, Hastrup H, Haahr H. Ultra-long-acting insulin degludec has a flat and stable glucose-lowering effect in type 2 diabetes. Diabetes Obes Metab. 2012;14:944-950.
44. Gough SCL, Bhargava A, Jain R, et al. Low volume insulin degludec 200 units/mL once daily improves glycemic control similar to insulin glargine with a low risk of hypoglycemia in insulin-naïve patients with type 2 diabetes: a 26-week, randomized, controlled, multinational, treat-to-target trial: the BEGIN- LOW VOLUME trial. Diabetes Care. 2013;36:2536-2542.
45. Novo Nordisk. NCT01831765. Efficacy and safety of FIAsp compared to Iinsulin aspart both in combination with insulin detemir in adults with type 1 diabetes (Onset® 1). Available at: http://clinicaltrials.gov/ show/NCT01831765. Accessed December 12, 2013.
46. Novo Nordisk. NCT01819129. Efficacy and safety of FIAsp compared to insulin aspart in combination with insulin glargine and metformin in adults with type 2 diabetes. Available at: http://clinicaltrials.gov/ct2/ show/NCT01819129. Accessed November 15, 2013.
47. Novo Nordisk. NCT01850615. Ef ficacy and safety of FIAsp in a basal-bolus regimen versus basal insulin therapy, both in combination with metformin in adult subjects with type 2 diabetes. Available at: http://clinicaltrials.gov/ct2/show/NCT01850615. Accessed November 15, 2013.
48. Biodel. NCT01908894. Pharmacokinetic and pharmacodynamic properties of BIOD-123 and BIOD-125 compared to Humalog- in subjects with type 1 diabetes including assessments of injection site toleration. Available at: http://clinicaltrials.gov/ct2/show/NCT01 908894 Accessed December 12, 2013.
49. Biodel. NCT01686620. A study evaluating safety and efficacy of BIOD-123 compared to insulin lispro (HumalogOnset®). Available at: http:// clinicaltrials.gov/ct2/show/NCT0168662 Accessed November 15, 2013.
50. Krasner A, Pohl R, Simms P, et al. A review of a family of ultra-rapidacting insulins: formulation development. J Diabetes Sci Technol. 2012;6:786-796.
51. Vaughn DE, Yocum RC, Muchmore DB, et al. Accelerated pharmacokinetics and glucodynamics of prandial insulins injected with recombinant human hyaluronidase. Diabetes Technol Ther. 2009;11: 345-352.
52. Morrow l, Muchmore DB, Hompesch M, Ludington EA, Vaughn DE. Comparative pharmacokinetics and insulin action for three rapid-acting insulin analogs injected subcutaneously with and without hyaluronidase. Diabetes Care. 2013;36:273-275.
53. Hompesch M, Muchmore DB, Morrow l, Vaughn DE. Accelerated insulin pharmacokinetics and improved postprandial glycemic control in patients with type 1 diabetes after coadministration of prandial insulins with hyaluronidase. Diabetes Care. 2011;34:666-668.
54. Morrow l, Muchmore DB, Ludington EA, Vaughn DE, Hompesch M. Reduction in intrasubject variability in the pharmacokinetic response to insulin after subcutaneous co-administration with recombinant human hyaluronidase in healthy volunteers. Diabetes Technol Ther. 2011;13: 1039-1045.
55. United Kingdom Prospective Diabetes Study (UKPDS). Overview of 6 years' therapy of type II diabetes: a progressive disease (UKPDS 16). Diabetes. 1995;44:1249-1258, Erratum in Diabetes. 1996;45:1655.
56. Riddle MC, Rosenstock J, Gerich J. The treat-to-target trial: randomized addition of glargine or human NPH insulin to oral therapy of type 2 diabetic patients. Diabetes Care. 2003;26:3080-3086.
57. Fonseca V. Clinical significance of targeting postprandial and fasting hyperglycemia in managing type 2 diabetes mellitus. Curr Med Res Opin. 2003;19:635-641.
58. Woerle HJ, Neumann C, Zschau S, et al. Impact of fasting and postprandial glycemia on overall glycemic control in type 2 diabetes Importance of postprandial glycemia to achieve target HbA1c levels. Diabetes Res Clin Pract. 2007;77:280-285.
59. Garber AJ. Hypoglycaemia: a therapeutic concern in type 2 diabetes. Lancet. 2012;379:2215-2216.
60. Inzucchi SE, Bergenstal RM, Buse JB, et al. Management of hyperglycemia in type 2 diabetes: a patient-centered approach: position statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35:1364-1379, Erratum in Diabetes Care. 2013;36:490.
61. Garber AJ, Abrahamson MJ, Barzilay JI, et al. AACE comprehensive diabetes management algorithm 2013. Endocr Pract. 2013;19: 327-336.
62. Stonehouse AH, Holcombe JH, Kendall DM. Management of Type 2 diabetes: the role of incretin mimetics. Expert Opin Pharmacother. 2006;7:2095-2105.
63. Holst JJ, Vilsboll T. Combining GLP-1 receptor agonists with insulin: therapeutic rationales and clinical findings. Diabetes Obes Metab. 2013;15:3-14.
64. Vora J, Bain SC, Damci T, et al. Incretin-based therapy in combination with basal insulin: a promising tactic for the treatment of type 2 diabetes. Diabetes Metab. 2013;39:6-15.
65. Vora J. Combining incretin-based therapies with insulin: realizing the potential in type 2 diabetes. Diabetes Care. 2013;36(Suppl 2): S226-S232, Erratum in Diabetes Care. 2013;36:4172.
66. Levin P, Wei W, Wang L, et al. Combination therapy with insulin glargine and exenatide: real-world outcomes in patients with type 2 diabetes. Curr Med Res Opin. 2012;28:439-446.
67. Levin PA, Mersey JH, Zhou S, Bromberger LA. Clinical outcomes using long-term combination therapy with insulin glargine and exenatide in patients with type 2 diabetes mellitus. Endocr Pract. 2012;18: 17-25.
68. Riddle MC, Aronson R, Home P, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled by established basal insulin: a 24-week, randomized, placebo-controlled comparison (GetGoal-L). Diabetes Care. 2013;36:2489-2496.
69. Riddle MC, Forst T, Aronson R, et al. Adding once-daily lixisenatide for type 2 diabetes inadequately controlled with newly initiated and continuously titrated basal insulin glargine: a 24-week, randomized, placebo-controlled study (GetGoal-Duo 1). Diabetes Care. 2013;36: 2497-2503.
70. Barnett AH, Charbonnel B, Donovan M, Fleming D, Chen R. Effect of saxagliptin as add-on therapy in patients with poorly controlled type 2 diabetes on insulin alone or insulin combined with metformin. Curr Med Res Opin. 2012;28:513-523.
71. Rosenstock J, Rodbard HW, Bain SC, et al. One-year sustained glycemic control and weight reduction in type 2 diabetes after addition of liraglutide to metformin followed by insulin detemir according to HbA target. J Diabetes Complications. 2013;27:492-500.
72. Mathieu C, Rodbard HW, Cariou B, et al. A comparison of adding liraglutide versus a single daily dose of insulin aspart to insulin degludec in subjects with type 2 diabetes (BEGIN: VICTOZA ADDON). Diabetes Obes Metab. 2014;16:636-644.
73. Gough SCL, Bode B, Woo V, et al. Efficacy and safety of a fixed-ratio combination of insulin degludec and liraglutide compared to each of its components given alone: results of a phase 3, randomised, 26-week, treat-to-target trial in insulin-naïve patients with type 2 diabetes. LancetDiabetes Endocrinol. 2014. http://dx.doi.org/10.1016/S2213-8587(14)70174-3.
74. Buse JB, Vilsbøll T, Thurman J, et al. The fixed ratio combination of insulin degludec and liraglutide in a randomized clinical trial: a novel alternative to basal insulin in the management of type 2 diabetes. Diabetes Care. 2014: in press.
75. Novo Nordisk. NCT01618162. The ef fi cacy of insulin degludec/ liraglutide as add-on therapy in controlling glycaemia in adults with type 2 diabetes inadequately controlled on sulphonylurea with or without metformin therapy (DUAL ™IV). Available at: http:// clinicaltrials.gov/show/NCT01618162. Accessed December 12, 2013.
76. Novo Nordisk. NCT01676116. The efficacy of insulin degludec/liraglutide in controlling glycaemia in adults with type 2 diabetes inadequately controlled on GLP-1 receptor agonist and OAD therapy (DUAL™ III). Available at: http://clinicaltrials.gov/show/NCT01 676116 Accessed November 15, 2013.
77. Sanofi. NCT01476475. Efficacy and safety of insulin glargine/gixisenatide fixed combination versus insulin glargine alone on top of metformin in type 2 diabetic patients. Available at: http://clinicaltrials. gov/ct2/show/NCT01476475. Accessed November 15, 2013.
78. Arbit E, Kidron M. Oral insulin: the rationale for this approach and current developments. J Diabetes Sci Technol. 2009;3:562-567.
79. Fonte P, Araujo F, Reis S, Sarmento B. Oral insulin delivery: how far are we? J Diabetes Sci Technol. 2013;7:520-531.
80. Generex Biotechnology Corp. NCT00948493. Treatment use of Generex Oral-lyn™ in patients with diabetes. Available at: http:// clinicaltrials.gov/show/NCT00948493. Accessed December 12, 2013.
81. Generex Biotechnology Corp. NCT00668850. Active comparator study of Generex Oral-lyn™ spray and injected human insulin. Available at: http://clinicaltrials.gov/show/NCT00668850. Accessed December 12, 2013.
82. Generex Biotechnology Corp. Generex Oral-lyn. Available at: http:// www.generex.com/index.php/id/270. Accessed December 12, 2013.
83. Eldor R, Arbit E, Corcos A, Kidron M. Glucose-reducing effect of the ORMD-0801 oral insulin preparation in patients with uncontrolled type 1 diabetes: a pilot study. PLoS One. 2013;8:e59524.
84. Eldor R, Arbit E, Schurr D, Kidron M, Hersko A. Dose response to oral insulin capsules in fasting, healthy subjects. Diabetes. 2013;62(Suppl 1):A272.
85. Rave K, Heise T, Pfutzner A, Boss AH. Coverage of postprandial blood glucose excursions with inhaled technosphere insulin in comparison to subcutaneously injected regular human insulin in subjects with type 2 diabetes. Diabetes Care. 2007;30:2307-2308.
86. Rave K, Potocka E, Heinemann L, et al. Pharmacokinetics and linear exposure of AFRESA compared with the subcutaneous injection of regular human insulin. Diabetes Obes Metab. 2009;11:715-720.
87. Rosenstock J, Lorber DL, Gnudi L, et al. Prandial inhaled insulin plus basal insulin glargine versus twice daily biaspart insulin for type 2 diabetes: a multicentre randomised trial. Lancet. 2010;375:2244-2253.
88. Raskin P, Heller S, Honka M, et al. Pulmonary function over 2 years in diabetic patients treated with prandial inhaled Technosphere Insulin or usual antidiabetes treatment: a randomized trial. Diabetes Obes Metab. 2012;14:163-173.
89. Hovorka R. Closed-loop insulin delivery: from bench to clinical practice. Nat Rev Endocrinol. 2011;7:385-395.
90. Pickup JC. Management of diabetes mellitus: is the pump mightier than the pen? Nat Rev Endocrinol. 2012;8:425-433.
91. Ramchandani N, Heptulla RA. New technologies for diabetes: a review of the present and the future. Int J Pediatr Endocrinol. 2012; 2012:28.
92. Zisser H, Jovanovic L. OmniPod Insulin Management System: patient perceptions, preference, and glycemic control. Diabetes Care. 2006;29: 2175.
93. Lane WS, Weinrib SL, Rappaport JM, Przestrzelski T. A prospective trial of U500 insulin delivered by Omnipod in patients with type 2 diabetes mellitus and severe insulin resistance. Endocr Pract. 2010;16: 778-784.
94. Rosenfeld CR, Bohannon NJ, Bode B, et al. TheV-Go insulin delivery device used in clinical practice: patient perception and retrospective analysis of glycemic control. Endocr Pract . 2012;18: 660-667.
95. Food and Drug Administration Department of Health & Human Services. MiniMed 530G System. Available at: http://www.accessdata. fda.gov/cdrh-docs/pdf12/p120010a.pdf. Accessed December 12, 2013.
96. Traitel T, Cohen Y, Kost J. Characterization of glucose-sensitive insulin release systems in simulated in vivo conditions. Biomaterials. 2000;21:1679-1687.
97. Taylor MJ, Tanna S, Sahota T. In vivo study of a polymeric glucosesensitive insulin delivery system using a rat model. J Pharm Sci. 2010;99:4215-4227.